|
Respiratory Syncytial Virus (RSV) is a significant public health concern, particularly for infants, young children, and older adults, causing severe respiratory diseases. Recently, the FDA approved vaccines Abrysvo and Arexvy, which utilize the stable prefusion F (pre-F) protein to enhance immunity and effectively protect against RSV. Sino Biological provides a comprehensive collection of recombinant antigens and antibodies, including the RSV pre-F antigen, to advance the development of vaccines, therapeutic antibodies, and diagnostic assays.
|
